Skip to content

Batch information on every product pageTHC < 0.3%Shipped from France10% off when you sign up

Research tools

SBFI-26

An inhibitor of FABP5 and FABP7: it blocks the intracellular transport of anandamide. A research tool.

Unscheduled
Level of detail

Harm-reduction warning

No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.

C₂₈H₂₂O₄

CID 1002969

Family
ECS pharmacological toolTransport inhibitor
Molar mass
422.50 g/mol

Updated on

In plain terms

SBFI-26 is a laboratory molecule unrelated to hemp: it is found in no plant and is not a cannabinoid. It blocks two transport proteins, FABP5 and FABP7, that move anandamide around inside cells, which makes the level of this natural endocannabinoid rise in the mouse brain. It has been studied only on purified proteins, in cells and in mice; no study in humans was found.

Receptors and activity

Target network

PPARγAgonistWeak agonist: roughly 3-fold activation (cell assay, Berger et al. 2012)
  • Activates
  • Blocks or inhibits

The lower the cited value, the closer the target sits to SBFI-26: one ring per factor of 100. A target with no measured value stays on the edge.

Where these targets live

Where each target has been found in humans, according to the cited studies. The map shows the target, not an effect of SBFI-26.

Brain, side view
Body, front view
Blood

PPARγPPARγ found in 6 regions of the body

  1. Adipose tissuedenseHighest levels in adipose tissue1
  2. GutdenseHighly expressed in the large intestine1
  3. LiverpresentIntermediate levels in the liver1
  4. HeartpresentExpressed at lower levels in the heart2
  5. Immune cellspresentPresent in monocyte-derived macrophages3
  6. Blood vesselspresentVascular smooth muscle cells4

Map sources

  1. Fajas L et al. The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem, 1997 (new tab)
  2. Vidal-Puig AJ et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest, 1997 (new tab)
  3. Chinetti G et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocyte-derived macrophages. J Biol Chem, 1998 (new tab)
  4. Marx N et al. Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res, 1998 (new tab)

Cited values

  1. FABP5InhibitorKi = 930 nM · human34 out of 100

    Berger et al., PLoS ONE 2012 (new tab) · NBD-stearate displacement (fluorescence), purified human FABP5; competitive inhibition

  2. FABP7InhibitorKi = 400 nM · not specified in the text consulted40 out of 100

    Kaczocha et al., PLoS ONE 2014 (table 2) (new tab) · NBD-stearate displacement (fluorescence), purified protein; Ki of 3.9 µM on FABP3

  3. PPARαAgonistno measured value cited

    Weak agonist: roughly 2-fold activation (cell assay, Berger et al. 2012)

  4. PPARγAgonistno measured value cited

    Weak agonist: roughly 3-fold activation (cell assay, Berger et al. 2012)

Bar length follows the measured value (Ki, Kd, EC50 or IC50), on one scale shared by every entry, from 100 µM to 0.1 nM. A target with no cited value has no bar.

Pharmacology

SBFI-26 is an α-truxillic acid 1-naphthyl monoester, identified in 2012 by virtual screening of more than a million compounds. Its mechanism is indirect: it competitively inhibits FABP5 and FABP7, the proteins that carry anandamide to FAAH, the enzyme that degrades it (Berger et al. 2012; Hsu et al. 2017). The Ki values are 0.93 µM for FABP5, 0.4 µM for FABP7 and 3.9 µM for FABP3; it inhibits cellular anandamide accumulation without inhibiting FAAH. In mice (20 mg/kg intraperitoneally), it raised brain anandamide without changing PEA, OEA or 2-AG, and reduced nociception in inflammatory, visceral and neuropathic models; these effects were blocked by rimonabant and by GW6471, but neither by SR144528 nor by naloxone (Kaczocha et al. 2014). SBFI-26 does not bind CB1 as an agonist itself. Affinities remain in the micromolar range. At 5, 20 and 40 mg/kg in mice it produced neither conditioned place preference nor aversion, and no change in locomotor activity, object recognition or the social behaviours tested (Thanos et al. 2016). No study in humans was found.

Key sources.

History

Source
An entirely synthetic compound, not known in cannabis. Its α-truxillic acid core, a diaryl cyclobutane, is also the core of incarvillateine, a monoterpene alkaloid from Incarvillea sinensis (Berger et al. 2012).

Origin

Research tool

No biosynthetic pathway: SBFI-26 is a synthetic compound derived from α-truxillic acid. Its preparation gives several stereoisomers, and only the (S) form was found in the crystal structures (Hsu et al. 2017).

Classification

Family, origin and source verification

Family

ECS pharmacological tool › Transport inhibitor

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

No dedicated article.

References

  1. Berger WT et al. Targeting fatty acid binding protein (FABP) anandamide transporters, a novel strategy for development of anti-inflammatory and anti-nociceptive drugs. PLoS ONE, 2012 (new tab)PMID 23236415
  2. Kaczocha M et al. Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia. PLoS ONE, 2014 (new tab)PMID 24705380
  3. Thanos PK et al. Examination of the addictive and behavioral properties of fatty acid-binding protein inhibitor SBFI26. Front Psychiatry, 2016 (new tab)PMID 27092087
  4. Hsu HC et al. The antinociceptive agent SBFI-26 binds to anandamide transporters FABP5 and FABP7 at two different sites. Biochemistry, 2017 (new tab)PMID 28632393
  5. PubChem, SBFI-26, CID 1002969 (identifiers and properties) (new tab)

Identifiers

Names

IUPAC name
trans-(2S,4S)-3-naphthalen-1-yloxycarbonyl-2,4-diphenylcyclobutane-1-carboxylic acid
Other names
SBFI26 · SB-FI-26 · α-truxillic acid 1-naphthyl monoester

Identifiers

Formula
C₂₈H₂₂O₄
PubChem CID
1002969(new tab)
InChIKey
NVOKBONTLOAJKA-ZCCOPBOASA-N
SMILES
C1=CC=C(C=C1)[C@H]2C([C@@H](C2C(=O)OC3=CC=CC4=CC=CC=C43)C5=CC=CC=C5)C(=O)O

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.